DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ulipristal Emergency Contraception Used Before or After Ovulation

Information source: The University of Hong Kong
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Contraception

Intervention: Ulipristal acetate (Drug)

Phase: N/A

Status: Completed

Sponsored by: The University of Hong Kong

Official(s) and/or principal investigator(s):
Hang Wun Raymond Li, MBBS, FRCOG, Principal Investigator, Affiliation: The University of Hong Kong


This was a prospective, open-label, single-drug, uncontrolled, observational clinical study. Women attending the Family Planning Association of Hong Kong (FPAHK) for emergency contraception within 120 hours of UPSI were recruited. Subjects were recruited from both the Birth Control Clinics and Youth Health Care Centres of the FPAHK. Depending on the timing in relation to ovulation in the current menstrual cycle at the time of presentation, the women were classified into two groups: Group 1: pre-ovulatory Group 2: post-ovulatory After counseling and obtaining informed consent, eligible subjects received a single dose of ulipristal acetate 30 mg (ellaOne®) under direct supervision. A baseline blood test for hormonal profile (LH, oestradiol and progesterone) and ultrasound scan for ovarian follicle assessment were carried out by a designated doctor or research nurse at the clinic visit. The subjects were advised not to have further acts of coitus before the return of menstruation. They were given a diary chart to record vaginal spotting and bleeding, possible side effects and further acts of intercourse, if any, and the contraceptive method used. A follow-up appointment were be arranged about 1-2 weeks after the expected next menstruation. Any events of unplanned pregnancy and adverse effects were recorded for analysis.

Clinical Details

Official title: Observational Study on the Clinical Efficacy of Ulipristal for Emergency Contraception When Administered Before or After Ovulation

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: percentage of pregnancies prevented

Secondary outcome:

failure rate

incidence of shortening or lengthening of the index menstrual cycle


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria: 1. Healthy women aged 18 years or above; 2. Regular menstrual cycles (every 21-35 days) within the past three cycles; 3. Requesting emergency contraception within 120 h of a single act of unprotected intercourse in the current menstrual cycle; 4. Willing to abstain from further acts of unprotected intercourse and; 5. Available for follow-up over the next 6 weeks Exclusion Criteria: 1. Post-abortion or postpartum patients whose period had not yet returned 2. Regular use of prescription drugs before admission to the study and 3. Intercourse during the treatment cycle more than 120 h before admission into the study. 4. Found pregnant at the time of presentation 5. Breastfeeding women 6. Women who have been sterilized (or partner being sterilized) or have intrauterine contraceptive device in-situ 7. Uncertain about the date of the last menstrual period 8. Women who had used hormonal contraceptive in the current or past one cycle

Locations and Contacts

Additional Information

Starting date: May 2011
Last updated: August 4, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017